retatrutide phase 2 nejm 2023 obesity trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 🤔 Adults with type 2

Electrolyte supplementation (sodium, potassium, magnesium) helps maintain proper hydration balance, particularly during the first few months when caloric intake drops most sharply

Everything beyond that is anecdote

(updated) Originally posted 8/29/25 Via the Massachusetts Division of Insurance: Merged Market Summary for Proposed Rates Effective for 2026 The following tables depict the proposed overall weighted average premium increase and the key assumptions behind premium development for the merged (individual and small employer) market filed by insurance carriers as part of the Massachusetts Division of Insurance rate review process (for rates effective in 2026)

Silencing "Food Noise" "Food noise" is that constant mental chatter telling you to eat snacks even when you aren't hungry

Implications: GLP-1 analogs have gained significant attention following the approval of liraglutide (Saxenda) for obesity treatment